Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980836 | 0.86 | AOC3 (0.40) | LMNAIDO1SCN4AAOC3 | |
| SCHEMBL23980839 | 0.86 | AOC3 (0.40) | LMNAIDO1SCN4AAOC3 | |
| SCHEMBL1496631 | 0.82 | KMT2A (0.51) | LMNAIDO1KDM4EL3MBTL1SCN4A | |
| SCHEMBL27287042 | 0.80 | AOC3 (0.36) | LMNAIDO1SCN4AAOC3 | |
| SCHEMBL26307498 | 0.76 | HTR2C (0.42) | IDO1KDM4E | |
| SCHEMBL6275695 | 0.76 | SCN4A (0.39) | LMNAIDO1SCN4A | |
| SCHEMBL23980799 | 0.76 | FAAH (0.36) | — | |
| SCHEMBL30217430 | 0.76 | FAAH (0.36) | — | |
| SCHEMBL1496739 | 0.75 | MEN1 (0.53) | LMNAKDM4ESCN4ALTA4H | |
| SCHEMBL30987975 | 0.75 | LMNA (0.61) | LMNAKDM4EL3MBTL1SCN4ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4143183-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115667250-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LMNA 3670/4885IDO1 2340/4885KDM4E 3398/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | LMNA 1610/4885IDO1 1868/4885KDM4E 4087/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LMNA 3670/4885IDO1 2340/4885KDM4E 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.